Patients using GLP-1 receptor agonists, such as Wegovy, Ozempic, and Mounjaro, are reporting a secondary effect: a diminished desire to consume alcohol. These medications, designed for weight loss, mimic hormones that regulate appetite and fullness. Research suggests these drugs also impact the brain’s reward centers, potentially lowering cravings for substances like alcohol and nicotine.
For some users, like Lisa Rees and Warren Thomas, the medication has significantly reduced their alcohol intake. Rees, who previously consumed multiple bottles of wine during social outings, now finds she physically cannot finish more than a couple of glasses. Thomas reported an immediate loss of interest in alcohol shortly after starting his treatment, noting that his tolerance has dropped to nearly zero.
However, the experience is not universal. Some users, such as student Faye Goodwin, have reported negative physical reactions like nausea and acid reflux, which have complicated their social lives. Goodwin noted that the timing of her injections often dictates her ability to attend social events where alcohol is prevalent, occasionally leading her to skip gatherings to avoid illness.
Medical professionals, including Professor Russell Hearn and Dr. Christian Hendershot, emphasize that while observational data and early studies are promising, there is no official medical guidance suggesting these drugs as a formal treatment for alcohol use disorder. Further large-scale clinical trials are required to confirm efficacy and ensure safety for broader use. While current users often view the reduction in drinking as a positive outcome for their weight-loss goals, researchers continue to investigate the long-term implications and potential for treating other forms of addiction.
